[go: up one dir, main page]

AU2001278696A1 - Aqueous pharmaceutical compositions - Google Patents

Aqueous pharmaceutical compositions

Info

Publication number
AU2001278696A1
AU2001278696A1 AU2001278696A AU7869601A AU2001278696A1 AU 2001278696 A1 AU2001278696 A1 AU 2001278696A1 AU 2001278696 A AU2001278696 A AU 2001278696A AU 7869601 A AU7869601 A AU 7869601A AU 2001278696 A1 AU2001278696 A1 AU 2001278696A1
Authority
AU
Australia
Prior art keywords
aqueous pharmaceutical
pharmaceutical composition
administration
ofloxacin
antibacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001278696A
Inventor
Masanobu Kirita
Hidekazu Suzuki
Masanobu Takeuchi
Takahiro Wada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakamoto Pharmaceutical Co Ltd
Original Assignee
Wakamoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co Ltd filed Critical Wakamoto Pharmaceutical Co Ltd
Publication of AU2001278696A1 publication Critical patent/AU2001278696A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration, thereby attaining high availability of a pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v% of methylcellulose, the 2 w/v% aqueous solution of which has a viscosity of 12 mPa.s or below at 20 DEG C; 1.5 to 2.3 w/v% of citric acid; 2 to 4 w/v% of polyethylene glycol; and 0.1 to 0.5 w/v% of ofloxacin.
AU2001278696A 2000-08-08 2001-08-08 Aqueous pharmaceutical compositions Abandoned AU2001278696A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000240455A JP3450805B2 (en) 2000-08-08 2000-08-08 Aqueous pharmaceutical composition
JP2000-240455 2000-08-08
PCT/JP2001/006805 WO2002011734A1 (en) 2000-08-08 2001-08-08 Aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
AU2001278696A1 true AU2001278696A1 (en) 2002-02-18

Family

ID=18731808

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001278696A Abandoned AU2001278696A1 (en) 2000-08-08 2001-08-08 Aqueous pharmaceutical compositions

Country Status (13)

Country Link
US (2) US20030194441A1 (en)
EP (1) EP1312366B1 (en)
JP (1) JP3450805B2 (en)
KR (1) KR20030040384A (en)
CN (1) CN1446092A (en)
AT (1) ATE376423T1 (en)
AU (1) AU2001278696A1 (en)
CA (1) CA2421787A1 (en)
DE (1) DE60131088T2 (en)
HU (1) HUP0302690A3 (en)
NO (1) NO20030533L (en)
RU (1) RU2003106395A (en)
WO (1) WO2002011734A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004026953A1 (en) * 2002-09-18 2006-01-19 わかもと製薬株式会社 Transparent reversible thermogelled aqueous composition
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
JP2005008625A (en) * 2003-05-23 2005-01-13 Santen Pharmaceut Co Ltd Eye lotion containing quinolone-based antibacterial compound
ES2431640T3 (en) * 2003-08-21 2013-11-27 Sucampo Ag Ophthalmic composition comprising isopropyl ester of unoprostone and a viscosity agent
JP4947977B2 (en) * 2003-10-31 2012-06-06 わかもと製薬株式会社 Reversible thermogelling aqueous composition
WO2005079809A1 (en) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. Transparent latanoprost eye drops
JP2005263792A (en) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd Clear latanoprost eye lotion
US7658947B2 (en) * 2004-06-25 2010-02-09 Kimberly-Clark Worldwide, Inc. Thermo-gelling composition
JP2007277095A (en) * 2004-07-02 2007-10-25 Wakamoto Pharmaceut Co Ltd Reversible thermogelling aqueous composition containing azithromycin
JP2006036660A (en) * 2004-07-23 2006-02-09 Wakamoto Pharmaceut Co Ltd A poorly soluble drug-containing aqueous suspension thermal gel formulation
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
EP1845983B1 (en) * 2004-10-25 2010-04-07 Bausch & Lomb Incorporated Ophthalmic compositions and methods of using the same
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
CN101130083B (en) * 2007-08-07 2010-05-19 山东博士伦福瑞达制药有限公司 Ophthalmic composition, producing method and use of the same
ITMI20080289A1 (en) * 2008-02-22 2009-08-23 S I F I Societa Industria Farmaceutica Italia COMPOSITIONS OF GEMIFLOXACINE WITH HIGH EFFICIENCY ON EYE DISEASES
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
US7842725B2 (en) 2008-07-24 2010-11-30 Ecolab USA, Inc. Foaming alcohol compositions with selected dimethicone surfactants
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
DE102009021372A1 (en) * 2009-05-14 2010-11-18 Ursapharm Arzneimittel Gmbh Phosphate-free pharmaceutical composition for glaucoma treatment
CN102791270A (en) * 2010-01-07 2012-11-21 明尼苏达大学董事会 Methods and compositions for applying moxifloxacin to the ear
CN101843625B (en) * 2010-03-30 2012-02-08 重庆巴仕迪动物药业有限公司 Compound ofloxacin injection for livestock and preparation method thereof
EP2595603A1 (en) * 2010-07-21 2013-05-29 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
US9937258B2 (en) * 2013-07-17 2018-04-10 Dow Global Technologies Llc Composition for application to a nasal mucosa comprising a methylcellulose
CN104000777B (en) * 2014-05-21 2016-06-01 丽珠医药集团股份有限公司 A kind of levofloxacin preparation
CN104784101A (en) * 2015-03-05 2015-07-22 中国药科大学制药有限公司 Prescription and preparation method for tranilast gel and ointment
JP6473274B1 (en) * 2017-04-25 2019-02-20 わかもと製薬株式会社 Thermal gelation artificial tears
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
CN109260152A (en) * 2018-11-13 2019-01-25 禹州市中医院 A kind of lomefloxacin hydrochloride auristilla
CA3121155C (en) 2018-11-26 2023-09-05 Aiviva Biopharma, Inc. Pharmaceutical biodissolvable gels for drug delivery
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
AU2020317084A1 (en) * 2019-07-23 2022-03-03 Nicox Ophthalmics, Inc. Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions
WO2022010906A1 (en) 2020-07-06 2022-01-13 Ecolab Usa Inc. Peg-modified castor oil based compositions for microemulsifying and removing multiple oily soils
AU2021306707B2 (en) 2020-07-06 2024-06-13 Ecolab Usa Inc. Foaming mixed alcohol/water compositions comprising a structured alkoxylated siloxane
EP4176032A1 (en) 2020-07-06 2023-05-10 Ecolab USA Inc. Foaming mixed alcohol/water compositions comprising a combination of alkyl siloxane and a hydrotrope/solubilizer
CN117338787A (en) * 2023-11-24 2024-01-05 南京恒道医药科技股份有限公司 Ophthalmic pharmaceutical composition and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (en) * 1987-11-13 1993-03-11 Asta Pharma Ag MEDICINAL PRODUCTS CONTAINING AZELASTIN FOR USE IN THE NOSE AND / OR EYE.
ATE189772T1 (en) * 1993-04-16 2000-03-15 Wakamoto Pharma Co Ltd WATER-BASED MEDICAL COMPOSITION THAT GELS REVERSIBLY UNDER HEAT
FI971533A7 (en) * 1994-10-13 1997-04-11 Wakamoto Pharma Co Ltd Lyophilized pharmaceutical preparations capable of forming an aqueous pharmaceutical composition having the property of reversible, thermosetting gelation
FI973060A0 (en) * 1995-01-20 1997-07-18 Wakamoto Pharma Co Ltd Anti-inflammatory eye drops
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
AU5342498A (en) * 1997-01-10 1998-08-03 Wakamoto Pharmaceutical Co., Ltd. Difluprednate-containing ophthalmic o/w emulsion composition
AU9281698A (en) * 1997-10-01 1999-04-23 Wakamoto Pharmaceutical Co., Ltd. O/w emulsion compositions
US6171616B1 (en) * 1998-04-13 2001-01-09 Shin-Etsu Chemical Co., Ltd. Solid preparation and a method of manufacturing it
WO1999059634A1 (en) * 1998-05-15 1999-11-25 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
WO1999063968A1 (en) * 1998-06-10 1999-12-16 Wakamoto Pharmaceutical Co., Ltd. Aqueous preparations containing hardly soluble drug
JP2001048807A (en) * 1999-08-04 2001-02-20 Wakamoto Pharmaceut Co Ltd Formulation of a poorly soluble drug dissolved in water
WO2001037838A1 (en) * 1999-11-24 2001-05-31 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
JP4541504B2 (en) 2000-06-14 2010-09-08 沢井製薬株式会社 A stable aqueous solution formulation containing tranilast or a pharmacologically acceptable salt thereof as an active ingredient
JP2002097129A (en) * 2000-07-21 2002-04-02 Rohto Pharmaceut Co Ltd Eye lotion

Also Published As

Publication number Publication date
ATE376423T1 (en) 2007-11-15
US7612115B2 (en) 2009-11-03
DE60131088D1 (en) 2007-12-06
CA2421787A1 (en) 2003-02-04
JP3450805B2 (en) 2003-09-29
EP1312366A8 (en) 2003-11-12
KR20030040384A (en) 2003-05-22
RU2003106395A (en) 2004-07-27
NO20030533D0 (en) 2003-02-03
DE60131088T2 (en) 2008-07-31
JP2003160473A (en) 2003-06-03
HUP0302690A3 (en) 2004-06-28
EP1312366B1 (en) 2007-10-24
NO20030533L (en) 2003-02-26
US20060172969A1 (en) 2006-08-03
EP1312366A4 (en) 2006-04-26
EP1312366A1 (en) 2003-05-21
WO2002011734A1 (en) 2002-02-14
CN1446092A (en) 2003-10-01
US20030194441A1 (en) 2003-10-16
HUP0302690A2 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
AU2001278696A1 (en) Aqueous pharmaceutical compositions
BR0211028A (en) Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2001032130A3 (en) Phenyl amine carboxylic acid compounds and compositions for delivering active agents
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
BRPI0411678A (en) nanoparticles of hyaluronic acid
WO2002048148A3 (en) Pyrazolopyridine derivatives
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
BR0007294A (en) Improved pharmaceutical formulations
NO20010863D0 (en) New oral formulations for 5-HT 4 agonists or antagonists
EP1250925A3 (en) Nasal spray containing ondansetron hydrochloride
WO2020025742A9 (en) Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
ATE420638T1 (en) STABLE SOLID MEDICAL COMPOSITION FOR ORAL ADMINISTRATION OF RAMOSETRON
MX2022016263A (en) Cyclobutyl-urea derivatives.
DE69224071D1 (en) COMPOSITIONS CONTAINING CHINOLANE AND ANTIBIOTICS AND POLYSTYRENE SULFONATE
PT1427417E (en) 3-substituted 6,7-dihydroxytetrahydroisoquinoline derivatives for use as antibacterial agents
ATE324103T1 (en) CONTROLLED RELEASE MEDICINAL PREPARATION CONTAINING TRAMADOL HYDROCHLORIDE
WO2004069187A3 (en) Drug formulation and delivery using crystalline methylated cyclodextrins
WO2005060361A3 (en) Pharmaceutical formulations for itraconazole
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
CA3188980A1 (en) Phytonadione compositions
JP4707316B2 (en) Aqueous liquid composition
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification
MXPA02003731A (en) Novel fusidic acid derivatives.
WO2002041875A3 (en) Method for producing readily soluble medicament formulations and corresponding formulations